1,676
Views
7
CrossRef citations to date
0
Altmetric
Pancreatic cancer

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

, , , , , , , , , , , , , , , , , , & show all
Pages 993-1000 | Received 03 Dec 2014, Accepted 21 Mar 2015, Published online: 30 Apr 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Nauman S. Siddiqui, Amandeep Godara, Margaret M. Byrne & Muhammad Wasif Saif. (2019) Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy 20:4, pages 399-409.
Read now
Bengt Glimelius. (2016) Any progress in pancreatic cancer?. Acta Oncologica 55:3, pages 255-258.
Read now

Articles from other publishers (5)

Hannes Treiber, Christian von der Brelie, Vesna Malinova, Dorothee Mielke, Veit Rohde & Claudia Ilse Chapuy. (2022) Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity. Neurosurgical Review 45:5, pages 3201-3208.
Crossref
Satoshi Nishioka, Tomomi Watanabe, Masaki Asano, Tatsunori Yamamoto, Kazuyoshi Kawakami, Shuntaro Yada, Eiji Aramaki, Hiroshi Yajima, Hayato Kizaki & Satoko Hori. (2022) Identification of hand-foot syndrome from cancer patients’ blog posts: BERT-based deep-learning approach to detect potential adverse drug reaction symptoms. PLOS ONE 17:5, pages e0267901.
Crossref
Xiaonan Yin, Zhou Zhao, Yuan Yin, Chaoyong Shen, Xin Chen, Zhaolun Cai, Jian Wang, Zhixin Chen, Yiqiong Yin & Bo Zhang. (2021) Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis. Clinical and Translational Science 14:3, pages 919-933.
Crossref
Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto Pazo-Cid, Fernando Rivera, Teresa García García, Olbia Serra, Eva Ma Fernández Parra, Alicia Hurtado, Ma José Gómez Reina, Luis Jesús López Gomez, Esther Martínez Ortega, Manuel Benavides & Enrique Aranda. (2017) Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. European Journal of Cancer 75, pages 73-82.
Crossref
Jiezhong Chen, Kristin Kaley, Marie Carmel Garcon, Teresa Rodriguez & Muhammad Wasif Saif. (2015) A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Therapeutic Advances in Gastroenterology 9:2, pages 162-168.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.